Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 213.00 | |
25 mg | In stock | $ 428.00 | |
50 mg | In stock | $ 639.00 | |
100 mg | In stock | $ 890.00 | |
500 mg | In stock | $ 1,830.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 147.00 |
Description | Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis. |
Targets&IC50 | Hepsin:0.33 μM |
In vitro | Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage[1]. |
In vivo | HepIn-13 displays dose-dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes in LPB-Tag/PB-Hepsin mice and blocks prostate cancer metastasis in this animal model. |
Synonyms | Hepln 13, Hepln13 |
Molecular Weight | 325.2 |
Formula | C17H13BrN2 |
CAS No. | 64369-13-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (184.50 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Hepln-13 64369-13-7 Tyrosine Kinase/Adaptors c-Met/HGFR potent non-toxic overexpression-relevant phenotypes orally inhibit Hepln 13 prostate cancer Inhibitor Hepln13 inhibitor